-
公开(公告)号：US20240226204A9
公开(公告)日：2024-07-11
申请号：US18546690
申请日：2022-02-18
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. , Otto-von-Guericke-Universität Magdeburg , Helmholtz-Zentrum für Infektionsforschung GmbH
发明人： Sascha KUPKE , Udo REICHL , Marc Dominique HEIN , Dunja BRUDER , ulfert RAND
摘要： In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
-
公开(公告)号：US20240131094A1
公开(公告)日：2024-04-25
申请号：US18546690
申请日：2022-02-18
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. , Otto-von-Guericke-Universität Magdeburg , Helmholtz-Zentrum für Infektionsforschung GmbH
发明人： Sascha KUPKE , Udo REICHL , Marc Dominique HEIN , Dunja BRUDER , ulfert RAND
摘要： In The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
-
搜索结果
2 条记录 (耗时 0.025 秒)
